Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus

Inclusion Criteria: 1. At least 18 years of age or older 2. Willingness to provide signed, informed consent to participate in the study 3. Presence of unwanted hair, moderate or greater benign pigmented lesions, active acne, vascular lesions, nails affected with onychomycosis, and/or wrinkles assessed as Fitzpatrick Wrinkle and Elastosis Score (FWS) \>/= 1 4. Willingness to adhere to study treatment and follow-up schedule 5. Willingness to adhere to post-treatment care instructions 6. Willingness to allow photographs and/or video of treated areas, and to release their use for scientific/educational and/or promotional/marketing purposes 7. Willing to abstain from any other procedures, medications or topicals in the study treatment areas for the duration of the study which the investigator deems would interfere with the study Exclusion Criteria: 1. Pregnant, planning pregnancy during the study, or breast feeding 2. Blonde, grey, or white hair in subjects seeking hair removal 3. Tattooed skin in the intended treatment area 4. Active sun tan in the intended treatment area 5. History of active Herpes Virus Simplex (HSV) or similar condition in the intended treatment area unless treated with prophylactic medication 6. History of melanoma 7. History of vitiligo in the intended treatment area 8. History of keloid or hypertrophic scar formation 9. History of Melasma in the intended treatment area or per Investigator's discretion 10. Severe immunosuppression resulting from medications and/or a medical condition that could impair healing after treatment 11. Open wound or infection in the intended treatment area 12. History of light induced seizure disorders 13. The subject is not suitable, in the opinion of the Investigator, for participation in the study due to inability to adhere to the study requirements, medical, or other reasons that could compromise the study integrity or subject safety 14. Dermatologic and/or cosmetic procedures including use of medications, or topicals in the intended treatment area(s) during a timepoint prior to the study that the investigator deems the subject unsuitable for the study